Navigation Links
Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
Date:4/10/2008

- Laureate To Manufacture Alopexx's Product Candidate -

PRINCETON, N.J., April 10, 2008 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the agreement, Laureate will produce Alopexx's mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and prevention of Staphylococcus aureus infections. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased that Alopexx chose Laureate Pharma as their manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will closely collaborate with the Alopexx team and help them drive their product from development into the clinic."

"Laureate Pharma has a track record of demonstrated expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said Dr. Daniel Vlock, President and CEO of Alopexx. "We look forward to our partnership with Laureate and advancing our antibody therapeutics program into the clinic."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE) (http://www.safeguard.com). For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com .

About Alopexx Pharmaceuticals, LLC

Alopexx Pharmaceuticals was founded to develop a promising new treatment for serious Staphylococcus aureus infections, including those caused by methicillin-resistant strains known as MRSA. In the past decade MRSA has emerged as a major public health problem. Due to the increasing volume of antimicrobial usage around the world, MRSA and many bacteria have become increasingly resistant to most commonly used antibiotics. mAb F598 is a fully human monoclonal antibody that has the potential to serve as an alternative to antibiotics in the fight against MRSA and other S. aureus infections. Unlike antibiotics, monoclonal antibodies will not lead to the development of bacterial resistance. The target of the antibody is a carbohydrate on the bacterial capsule known as PNAG. PNAG has been found to be a critical factor in the virulence and immune response to MRSA as well as non-MRSA staphylococcal infections and is also expressed by other bacterial pathogens. Alopexx Pharmaceuticals, LLC was co-founded by Gerald Pier, PhD and Daniel Vlock, MD. Its aim is to develop and explore the use of novel therapies for the treatment and prevention of MRSA and other serious infections. For more information contact Daniel Vlock, MD at 617-780-1598 or daniel.vlock@alopexx.com or visit http://www.alopexx.com .


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Laureate Pharma Reports Record Growth for 2007
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. ... be presenting at the Annual Biocom Global Life Science ... 2, at 11:15 AM, at the Torrey Pines Lodge, ... to the organizers at Biocom who have chosen our ... symposium of biotechnology companies, investors, and clinical researchers," said ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... provider of women’s health, primary care, and specialty education, announced today it ... Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and is ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, is pleased to ... on February 22 and 23, 2017. This premier, online-only conference focused on the ...
(Date:2/22/2017)... Dublin - Research and Markets has announced ... Type, By Application, By End User, By Region, By Country: Opportunities ... ... is forecasted to grow at a CAGR of 11.33% during 2016-2021. ... protection market is driven by the surging demand for less toxic ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):